DiaGenic

DiaGenic is a Norwegian biotechnology company that develops patient-friendly, blood-based diagnostic tests for early detection of diseases, particularly Alzheimer’s disease and breast cancer. Their platform uses patented gene expression analysis in peripheral blood to identify disease-specific biomarkers. The company has CE-marked diagnostic tests (BCtect® for breast cancer, ADtect® for Alzheimer’s) and collaborates with pharmaceutical companies to develop companion diagnostics and accelerate clinical trial recruitment. Early results from their Alzheimer’s biomarker research in collaboration with Pfizer are promising, suggesting potential for improved early diagnosis and monitoring of disease progression[1][3][4].